Abbreviation: PTLD, post-transplant lymphoproliferative disorder; TCR, T-cell gene rearrangement; EBV, Epstein Barr virus; CHOP, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and the steroid hormone prednisone. EPOCH, etoposide phosphate, prednisone, vincristine sulfate (Oncovin), cyclophosphamide, and doxorubicin hydrochloride (hydroxydaunorubicin). ASCT, autologous stem cell transplant. N/A, not available.

Figure 1: Pathology features of plasmablastic lymphoma post solid organ transplant. A-B, the H&E section of intestinal mass (H&E, A, 20X; B, 400x) and the touch imprint (C, Diff-Quick stain,1000x) shows a diffuse infiltrate of plasmablastic tumor cells. By immunohistochemical stain, the tumor cells are negative for CD20 (not shown); positive for patchy CD79a (D, 200X), CD30 (E, 200X), cytoplasmic CD3 (F, 200X), high Ki67 proliferation rate (G, 200X); negative for EBER in situ hybridization (H, 200X). Most tumor cells are negative for CD138 (I, 200x).